Douglas C. Bryant Sells 69,168 Shares of Quidel Corp. (QDEL) Stock
Quidel Corp. (NASDAQ:QDEL) CEO Douglas C. Bryant sold 69,168 shares of Quidel Corp. stock in a transaction on Friday, September 30th. The shares were sold at an average price of $21.76, for a total value of $1,505,095.68. Following the transaction, the chief executive officer now owns 291,121 shares of the company’s stock, valued at approximately $6,334,792.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Quidel Corp. (NASDAQ:QDEL) opened at 22.09 on Friday. The company’s market cap is $715.54 million. Quidel Corp. has a one year low of $13.21 and a one year high of $23.94. The company has a 50 day moving average price of $21.73 and a 200 day moving average price of $19.11.
Quidel Corp. (NASDAQ:QDEL) last released its quarterly earnings data on Wednesday, July 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.14. Quidel Corp. had a negative net margin of 6.59% and a negative return on equity of 1.06%. The company earned $39.10 million during the quarter, compared to the consensus estimate of $37.98 million. During the same quarter in the prior year, the firm posted ($0.14) earnings per share. Quidel Corp.’s revenue for the quarter was up 11.1% on a year-over-year basis. Equities analysts predict that Quidel Corp. will post ($0.14) EPS for the current year.
A number of institutional investors have recently added to or reduced their stakes in the stock. Brown Capital Management LLC boosted its stake in shares of Quidel Corp. by 0.4% in the second quarter. Brown Capital Management LLC now owns 5,748,536 shares of the company’s stock worth $102,669,000 after buying an additional 23,100 shares during the last quarter. Janus Capital Management LLC boosted its stake in shares of Quidel Corp. by 1.3% in the second quarter. Janus Capital Management LLC now owns 2,265,082 shares of the company’s stock worth $40,454,000 after buying an additional 29,825 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Quidel Corp. by 1.7% in the second quarter. Vanguard Group Inc. now owns 1,963,521 shares of the company’s stock worth $35,069,000 after buying an additional 32,681 shares during the last quarter. Macquarie Group Ltd. boosted its stake in shares of Quidel Corp. by 27.7% in the second quarter. Macquarie Group Ltd. now owns 858,387 shares of the company’s stock worth $15,331,000 after buying an additional 186,020 shares during the last quarter. Finally, BlackRock Fund Advisors boosted its stake in shares of Quidel Corp. by 0.9% in the second quarter. BlackRock Fund Advisors now owns 639,490 shares of the company’s stock worth $11,421,000 after buying an additional 5,764 shares during the last quarter. Institutional investors own 94.28% of the company’s stock.
QDEL has been the subject of a number of recent research reports. Zacks Investment Research cut Quidel Corp. from a “buy” rating to a “hold” rating in a research note on Saturday, July 23rd. Canaccord Genuity reiterated a “hold” rating and set a $22.00 price objective on shares of Quidel Corp. in a research note on Friday, July 29th. Finally, Raymond James Financial Inc. upgraded Quidel Corp. from a “market perform” rating to an “outperform” rating and set a $21.50 price objective for the company in a research note on Monday, June 13th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $21.58.
About Quidel Corp.
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. The Company’s diagnostic testing solutions primarily include applications in infectious diseases, women’s health and gastrointestinal diseases. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers.
Receive News & Stock Ratings for Quidel Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Corp. and related stocks with our FREE daily email newsletter.